{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:31:12Z","timestamp":1793183472806,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"23-24","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.cca.2010.08.039","type":"journal-article","created":{"date-parts":[[2010,9,4]],"date-time":"2010-09-04T10:41:48Z","timestamp":1283596908000},"page":"1869-1874","source":"Crossref","is-referenced-by-count":305,"title":["CA 15-3: Uses and limitation as a biomarker for breast cancer"],"prefix":"10.1016","volume":"411","author":[{"given":"Michael J.","family":"Duffy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Evoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enda W.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2010.08.039_bb0005","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ijc.1571","article-title":"Estimates of the world-wide prevalence of cancer for 25 sites in the adult population","volume":"97","author":"Pisani","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cca.2010.08.039_bb0010","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3816\/CBC.2005.n.043","article-title":"The global breast cancer burden: variations in epidemiology and survival","volume":"6","author":"Hortabagyi","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.cca.2010.08.039_bb0015","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(09)60316-0","article-title":"Early breast cancer","volume":"373","author":"Benson","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2010.08.039_bb0020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1470-2045(03)01037-4","article-title":"Why is breast cancer mortality declining","volume":"4","author":"Jatoi","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cca.2010.08.039_bb0025","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJMoa050518","article-title":"Effect of screening and adjuvant therapy on mortality from breast cancer","volume":"353","author":"Berry","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2010.08.039_bb0030","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1373\/clinchem.2008.105601","article-title":"National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancers","volume":"54","author":"Sturgeon","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2010.08.039_bb0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0009-9120(00)00201-0","article-title":"Biochemical markers in breast cancer: which ones are clinically useful?","volume":"34","author":"Duffy","year":"2001","journal-title":"Clin Biochem"},{"key":"10.1016\/j.cca.2010.08.039_bb0040","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1373\/clinchem.2004.046227","article-title":"Predictive markers in breast and other cancers: a review","volume":"51","author":"Duffy","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2010.08.039_bb0045","first-page":"211","article-title":"Biomarkers in breast cancer: use in aidind diagnosis, determining prognosis and predicting response to therapy. In: Breast Cancer: From Pathogenesis to Potential Therapeutic Modalities","author":"Duffy","year":"2009"},{"key":"10.1016\/j.cca.2010.08.039_bb0050","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.physiol.70.113006.100659","article-title":"Structure and function of the cell surface (tethered) mucins","volume":"70","author":"Hattrup","year":"2008","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.cca.2010.08.039_bb0055","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nrc2761","article-title":"Mucins in cancer: function, prognosis and therapy","volume":"9","author":"Kufe","year":"2009","journal-title":"Nature Rev Cancer"},{"issue":"278","key":"10.1016\/j.cca.2010.08.039_bb0060","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1074\/jbc.M208326200","article-title":"Tumor necrosis factor-alpha converting enzyme\/ADAM 17 mediates MUC1 shedding","volume":"31","author":"Thathiah","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cca.2010.08.039_bb0065","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1042\/BJ20040513","article-title":"MT1-MMP mediates MUC1 shedding independent of TACE\/ADAM17","volume":"382","author":"Thathiah","year":"2004","journal-title":"Biochem J"},{"issue":"22","key":"10.1016\/j.cca.2010.08.039_bb0070","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.onc.1206291","article-title":"MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion","volume":"6","author":"Schroeder","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.cca.2010.08.039_bb0075","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s10585-005-3098-x","article-title":"MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1","volume":"22","author":"Rahn","year":"2005","journal-title":"Clin Exp Metastasis"},{"issue":"96","key":"10.1016\/j.cca.2010.08.039_bb0080","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/jcb.20612","article-title":"Glycoprotein contributions to mammary gland and mammary tumor structure and function: roles of adherens junctions, ErbBs and membrane MUCs","volume":"1","author":"Carraway","year":"2005","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.cca.2010.08.039_bb0085","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1186\/bcr1515","article-title":"MUC1 alters oncogenic events and transcription in human breast cancer cells","volume":"8","author":"Hattrup","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.cca.2010.08.039_bb0090","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1038\/sj.onc.1206732","article-title":"Human DF3\/MUC1 carcinoma-associated protein functions as an oncogene","volume":"22","author":"Li","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.cca.2010.08.039_bb0095","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1158\/0008-5472.CAN-09-0854","article-title":"Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells","volume":"69","author":"Raina","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.cca.2010.08.039_bb0100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1023\/A:1011331809881","article-title":"O-linked glycosylation in the mammary gland: changes that occur during malignancy","volume":"6","author":"Burchell","year":"2001","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"10.1016\/j.cca.2010.08.039_bb0105","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1002\/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A","article-title":"The importance of muc1 cellular localization in patients with breast canrcinoma","volume":"91","author":"Rahn","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2010.08.039_bb0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1373\/clinchem.2005.059832","article-title":"Serum tumor markers in breast cancer: are they of clinical value?","volume":"52","author":"Duffy","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2010.08.039_bb0115","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/ctrv.1999.0151","article-title":"Tumour marker measurements in the diagnosis and monitoring of breast cancer","volume":"26","author":"Cheung","year":"2000","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cca.2010.08.039_bb0120","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1177\/000456329903600503","article-title":"CA 15-3 and related mucins as circulating markers in breast cancer","volume":"36","author":"Duffy","year":"1999","journal-title":"Ann Clin Biochem"},{"issue":"10","key":"10.1016\/j.cca.2010.08.039_bb0125","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.5858\/2004-128-1131-MGGAFM","article-title":"MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen?","volume":"128","author":"Klee","year":"2004","journal-title":"Arch Pathol Lab Med."},{"key":"10.1016\/j.cca.2010.08.039_bb0130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/hyb.1984.3.223","article-title":"Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors","volume":"3","author":"Kufe","year":"1984","journal-title":"Hybridoma"},{"key":"10.1016\/j.cca.2010.08.039_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000056500","article-title":"Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin","volume":"19","author":"Price","year":"1998","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cca.2010.08.039_bb0140","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1200\/JCO.1997.15.6.2322","article-title":"Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease","volume":"15","author":"Chan","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2010.08.039_bb0145","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1515\/CCLM.2009.213","article-title":"Comparison of fifteen immunoassays for the measurement of serum MUC-1\/CA 15-3 in breast cancer patients","volume":"47","author":"Pichon","year":"2009","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2010.08.039_bb0150","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.1986.4.10.1542","article-title":"Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer","volume":"4","author":"Hayes","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2010.08.039_bb0155","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1093\/clinchem\/47.12.2162","article-title":"Evaluation of the analytical and clinical performance of the Elecsys CA 15-3 immunoassay","volume":"47","author":"Stieber","year":"2001","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2010.08.039_bb0160","first-page":"15","article-title":"Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients","volume":"49","author":"Stieber","year":"2003","journal-title":"Clin Lab"},{"key":"10.1016\/j.cca.2010.08.039_bb0165","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/clinchem\/43.4.585","article-title":"Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays","volume":"43","author":"Bon","year":"1997","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2010.08.039_bb0170","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1002\/1097-0142(19921215)70:12<2831::AID-CNCR2820701218>3.0.CO;2-8","article-title":"CA 15-3 in patients with locoregional and metastatic breast carcinoma","volume":"70","author":"Geraghty","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2010.08.039_bb0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF01806524","article-title":"Circulating CA 15-3 levels in the postsurgical follow-up breast cancer patients and in non-malignant disease","volume":"13","author":"Colomer","year":"1989","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cca.2010.08.039_bb0180","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1507\/endocrj1954.36.873","article-title":"Changes in the tumor marker concentration in female patients with hyper, eu and hyperthyroidism","volume":"36","author":"Hashimoto","year":"1989","journal-title":"Endocrinol Jpn"},{"key":"10.1016\/j.cca.2010.08.039_bb0185","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000082919","article-title":"Increased serum CA 15-3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency","volume":"67","author":"Symeonidis","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.cca.2010.08.039_bb0190","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2521::AID-CNCR17>3.0.CO;2-A","article-title":"Preoperative CA 15-3 concentrations predict outcome in breast cancer","volume":"83","author":"Shering","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2010.08.039_bb0195","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1005734429304","article-title":"c-erbB-2 oncoprotein, CEA and CA 15-3 in patients with breast cancer","volume":"51","author":"Molina","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cca.2010.08.039_bb0200","first-page":"273","article-title":"Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis","volume":"22","author":"Canizares","year":"2002","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cca.2010.08.039_bb0205","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0959-8049(01)00426-9","article-title":"Prognostic role of serum CA 15.3 in 362 node-negative breast cancer. An old player for a new game","volume":"38","author":"Gion","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cca.2010.08.039_bb0210","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.bjc.6600248","article-title":"Serum CEA and CA 15-3 as prognostic factors in primary breast cancer","volume":"22","author":"Ebeling","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cca.2010.08.039_bb0215","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1023\/A:1020514925143","article-title":"Serum tumor marker CA 15.3 and stage are the two most important predictors of survival in primary breast cancer","volume":"76","author":"Kumpulainen","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cca.2010.08.039_bb0220","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1373\/clinchem.2009.135566","article-title":"Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen CA 15.3 (CA 15-3) in patients with primary locoregional breast cancer","volume":"56","author":"Molina","year":"2010","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2010.08.039_bb0225","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1373\/clinchem.2003.025288","article-title":"High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer","volume":"50","author":"Duffy","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2010.08.039_bb0230","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s13277-010-0025-9","article-title":"Evaluation of tumor markers (HER-2\/neu oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer: prognostic value","volume":"31","author":"Molina","year":"2010","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cca.2010.08.039_bb0235","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000089260","article-title":"Tumor markers in breast cancer - European Group on Tumor Markers recommendations","volume":"26","author":"Molina","year":"2005","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cca.2010.08.039_bb0240","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","article-title":"Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009","volume":"20","author":"Goldhirsch","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cca.2010.08.039_bb0245","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00690183","article-title":"Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients","volume":"36","author":"Molina","year":"1995","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cca.2010.08.039_bb0250","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ejca.2003.10.015","article-title":"Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA","volume":"40","author":"Soletormos","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cca.2010.08.039_bb0255","first-page":"1963","article-title":"Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients","volume":"27","author":"Laessig","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cca.2010.08.039_bb0260","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/1471-2407-6-269","article-title":"Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases","volume":"6","author":"Nicolini","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cca.2010.08.039_bb0265","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.2001.19.6.1865","article-title":"2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology","volume":"19","author":"Bast","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2010.08.039_bb0270","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","article-title":"American Society of Clinical Oncology 2007 Update of recommendations for the use of tumor markers in breast cancer","volume":"25","author":"Harris","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2010.08.039_bb0275","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/annonc\/mdp114","article-title":"ESMO Guideline Working Group. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Kataja","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cca.2010.08.039_bb0280","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Breast Cancer. Version 2, 2010. www.nccn.org\/professionals\/physician_gls\/f guidelines.asp (Accessed 19 April 2010)."},{"key":"10.1016\/j.cca.2010.08.039_bb0285","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1056\/NEJMcp067260","article-title":"Clinical practice. Follow-up of patients with early breast cancer","volume":"356","author":"Hayes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2010.08.039_bb0290","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/BD-2004-21107","article-title":"Rational surveillance programs for early stage breast cancer patients after primary treatment","volume":"21","author":"Mollick","year":"2009","journal-title":"Breast Dis"},{"key":"10.1016\/j.cca.2010.08.039_bb0295","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1477-7819-3-54","article-title":"Guidelines, guidelines and more guidelines: and we still do not know how to follow-up patients with breast cancer","volume":"3","author":"Heys","year":"2005","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.cca.2010.08.039_bb0300","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/bmj.39421.440799.BE","article-title":"Follow-up after breast cancer","volume":"336","author":"Dixon","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cca.2010.08.039_bb0305","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1001\/jama.271.20.1587","article-title":"The Givio Investigators: Impact of follow-up testing on survival and health-related quality of life in breast cancer patients A multicenter randomised controlled trial","volume":"271","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2010.08.039_bb0310","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/jama.271.20.1593","article-title":"Intensive diagnostic follow-up after treatment of primary breast cancer, a randomised trial. National Research Council Project on Breast Cancer follow-up","volume":"271","author":"Roselli del Turco","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2010.08.039_bb0315","first-page":"133","article-title":"The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements","volume":"3","author":"Jager","year":"1993","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.cca.2010.08.039_bb0320","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/bjc.1997.515","article-title":"Prolonged survival by \u2018early\u2019 salvage treatment of breast cancer patients: a retrospective 6-year study","volume":"76","author":"Nicolini","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cca.2010.08.039_bb0325","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/BF00686288","article-title":"Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial","volume":"35","author":"Kovner","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cca.2010.08.039_bb0330","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1373\/clinchem.2007.094144","article-title":"National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements","volume":"54","author":"Sturgeon","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2010.08.039_bb0335","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/jnci\/djp235","article-title":"International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy","volume":"101","author":"Cardoso","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cca.2010.08.039_bb0340","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0959-8049(98)00297-4","article-title":"The objective measurement of remission and progression in metastatic breast cancer by use of serum tumor markers","volume":"35","author":"Robertson","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cca.2010.08.039_bb0345","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0960-9776(96)90126-5","article-title":"Treatment response in metastatic breast cancer: a multicenter study comparing UICC criteria and tumor marker changes","volume":"5","author":"Van Dalen","year":"1996","journal-title":"Breast"},{"key":"10.1016\/j.cca.2010.08.039_bb0350","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF02968047","article-title":"Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study","volume":"11","author":"Kurebayashi","year":"2004","journal-title":"Breast Cancer"},{"key":"10.1016\/j.cca.2010.08.039_bb0355","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10549-005-9155-y","article-title":"Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients","volume":"98","author":"Tampellini","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cca.2010.08.039_bb0360","first-page":"38","article-title":"CA15-3 and CEA spikes during chemotherapy for metastatic breast cancer","volume":"7","author":"Hayes","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.cca.2010.08.039_bb0365","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0009-9120(96)00133-6","article-title":"Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on \u201cspiking\u201d phenomena","volume":"30","author":"Yasasever","year":"1997","journal-title":"Clin Biochem"},{"key":"10.1016\/j.cca.2010.08.039_bb0370","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10549-009-0377-2","article-title":"Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer","author":"Kim","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cca.2010.08.039_bb0375","first-page":"2551","article-title":"C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients","volume":"19","author":"Molina","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cca.2010.08.039_bb0380","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ejca.2003.10.015","article-title":"Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA","volume":"40","author":"Soletormos","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cca.2010.08.039_bb0385","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.clinbiochem.2004.05.009","article-title":"Clinical utility of cytokeratins as tumor markers","volume":"37","author":"Barak","year":"2004","journal-title":"Clin Biochem"},{"key":"10.1016\/j.cca.2010.08.039_bb0390","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000217747","article-title":"TPS in breast cancer\u2014a comparative study with carcinoembryonic antigen and CA 15\u20133","volume":"13","author":"van Dalen","year":"1992","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cca.2010.08.039_bb0395","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0960-9776(96)90126-5","article-title":"Treatment response in metastatic breast cancer: a multicenter study comparing UICC criteria and tumor marker changes","volume":"5","author":"van Dalen","year":"1996","journal-title":"Breast"},{"key":"10.1016\/j.cca.2010.08.039_bb0400","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/cncr.23689","article-title":"Serum HER-2\/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer","volume":"113","author":"Ali","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2010.08.039_bb0405","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/jnci\/88.20.1456","article-title":"Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers","volume":"88","author":"Hayes","year":"1996","journal-title":"J Natl Cancer Inst"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898110005589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898110005589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T08:45:45Z","timestamp":1636361145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898110005589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":81,"journal-issue":{"issue":"23-24","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0009898110005589"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2010.08.039","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}